An Eight-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Fixed Dose of SR58611A [amibegron] 350 mg Twice a Day in Elderly Patients With Generalized Anxiety Disorder With an Optional Twenty-Four Week Extension
Latest Information Update: 11 Apr 2022
At a glance
- Drugs Amibegron (Primary)
- Indications Generalised anxiety disorder
- Focus Therapeutic Use
- Sponsors Sanofi
- 07 Apr 2022 This trial has been completed in Slovakia (End Date: 29 Aug 2007), according to European Clinical Trials Database record.
- 24 Nov 2008 Actual patient number (55) added as reported by ClinicalTrials.gov
- 02 Nov 2008 Additional trial identifier 'EudraCT2006-004147-33' added as reported by ClinicalTrials.gov.